Conduent (CNDT) Stock Price, News & Analysis

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Conduent in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNDT shares.
View CNDT analyst ratings or view top-rated stocks.

1 equities research analysts have issued 12 month target prices for Conduent's stock. Their CNDT share price targets range from $9.00 to $9.00. On average, they anticipate the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 194.1% from the stock's current price.
View analysts price targets for CNDT or view top-rated stocks among Wall Street analysts.

Conduent's stock was trading at $3.65 at the beginning of 2024. Since then, CNDT shares have decreased by 16.2% and is now trading at $3.06.
View the best growth stocks for 2024 here.

Conduent saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 1,440,000 shares, a decline of 21.7% from the March 15th total of 1,840,000 shares. Based on an average daily trading volume, of 1,020,000 shares, the days-to-cover ratio is currently 1.4 days. Currently, 0.8% of the company's stock are short sold.
View Conduent's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our CNDT earnings forecast.

Conduent will be holding an earnings conference call on Wednesday, May 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 877-660-6853 with passcode "13745034".

Conduent Incorporated (NASDAQ:CNDT) released its quarterly earnings data on Wednesday, February, 14th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.01. The company earned $953 million during the quarter, compared to analysts' expectations of $930 million. The firm's revenue for the quarter was down 3.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.01 earnings per share.

LeaderShares Activist Leaders ETF holds 945,712 shares of CNDT stock, representing 3.59% of its portfolio.

Conduent updated its FY 2024 earnings guidance on Wednesday, February, 14th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.6 billion-$3.7 billion, compared to the consensus revenue estimate of $3.7 billion.

Based on aggregate information from My MarketBeat watchlists, some companies that other Conduent investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and

Conduent's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Counterpoint Mutual Funds LLC (0.04%) and Diversified Trust Co (0.02%). Insiders that own company stock include Clifford Skelton, Louis Edward Keyes, Mark Simon Brewer, Michael E Krawitz and Stephen Henry Wood.
View institutional ownership trends.

Shares of CNDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.